Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Market Cap	$50.78M	P/E Ratio	NaN
52W High	$5.12	52W Low	$0.24
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	28.2%	52W Position	82.6%
Overall Score	57	Value Score	40
Quality Score	--	Technical Score	75

EPS Current Est	$NA	EPS Next Est	$-0.05
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$4.27	-1.16%	1.18M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$4.27	-1.2%	1.18M
3
4
5
6

RLMD

RLMD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Relmada Therapeutics Inc. Data in Excel

Get Relmada Therapeutics Inc. Data in Excel